This proposal is for renewal of our postdoctoral research training grant in Immunohematology and Transfusion Medicine that was initiated in 2001. The program provides a highly organized 2-3 year program of focused dedicated didactics, seminars, and, most importantly, an intense research experience with one of 24 well-established, highly interactive, and well-funded cross-disciplinary mentors representing eight different primary departments. The goal is to generate productive MD and MD/PhD physician- scientists as well as PhD scientists and clinician-scientists, who will be launched on a lifelong investigative career pursuing basic and translational research in this underrepresented field. Careful career development by an individualized "Career &Research Committee" is a hallmark of the program. Three degree-granting "tracks" are also available, in addition to the core post-doctoral program: an Investigative Medicine PhD available to MD-only trainees who wish to obtain a more expansive research background mimicking that of an MD/PhD;a Masters of Health Sciences under the aegis of the Yale CTSA for those with a clinical/translational research goal;and a Masters of Biomedical Engineering for trainees with a past basic biomedicine emphasis who wish to add an engineering dimension to their knowledge base. Drawn from a candidate pool focused on those whose background is Laboratory Medicine &Pathology (a pool which has always included at least 10 fold more excellent candidates than are accepted into the program), outcomes have been quite positive. Of the graduates of the T32 program, 25% have successfully completed a degree-granting track, 50% have secured tenure track academic investigative positions, with the remainder retained in research at earlier career development stages;all have obtained some subsequent funding with 25% moving directly to K08 awards. The T32 program currently supports four post-doctoral positions per year and, based on results and candidate pool, we are requesting an increase to six positions. The "core" T32 is "leveraged", since the entire Laboratory Medicine Departmental Immunohematology-Transfusion Medicine training program is greater than the T32 - it includes individuals on other funding mechanisms. When they are included, 69% of graduates have investigative tenure track positions and 38% have attained PI-level R01 funding. We believe that this program fills an important research training need both at Yale and nationally.
As stated recently in the NIH program announcement PAR-10-034: Research aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine is critical to public health since about five million patients receive blood transfusions every yea in the U.S. It is critical to train the next generation of investigators who can conduct basic, translational, and clinical research in Immunohematology and Transfusion Medicine, in order to improve the effectiveness of immunotherapeutic cellular therapy and blood cell / bone marrow / stem cell transplantation techniques, enhance the safety of the blood supply by understanding pathogen interactions, understand the effects of transfusion on a patient's immune system, and bring new bioengineering technologies to improving all these areas of clinical care.
|Cheng, Christopher J; Bahal, Raman; Babar, Imran A et al. (2015) MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518:107-10|
|Fink, S L; Robey, T E; Tarabar, A F et al. (2014) Rapid detection of convallatoxin using five digoxin immunoassays. Clin Toxicol (Phila) 52:659-63|
|Cheng, Christopher J; Saltzman, W Mark; Slack, Frank J (2013) Canonical and non-canonical barriers facing antimiR cancer therapeutics. Curr Med Chem 20:3582-93|
|Williams, Adam; Lee, Gap Ryol; Spilianakis, Charalampos G et al. (2013) Hypersensitive site 6 of the Th2 locus control region is essential for Th2 cytokine expression. Proc Natl Acad Sci U S A 110:6955-60|
|Tormey, Christopher A; Smith, Brian R (2013) The transfusion medicine specialist as a coagulation consultant: a new variant of therapeutic pathology. Transfusion 53:2086-93|
|Nickerson, Kevin M; Christensen, Sean R; Cullen, Jaime L et al. (2013) TLR9 promotes tolerance by restricting survival of anergic anti-DNA B cells, yet is also required for their activation. J Immunol 190:1447-56|
|Eisenbarth, Stephanie C; Williams, Adam; Colegio, Oscar R et al. (2012) NLRP10 is a NOD-like receptor essential to initiate adaptive immunity by dendritic cells. Nature 484:510-3|
|Henao-Mejia, Jorge; Elinav, Eran; Jin, Chengcheng et al. (2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482:179-85|
|Anderson, Britt E; Tang, Anita L; Wang, Ying et al. (2011) Enhancing alloreactivity does not restore GVHD induction but augments skin graft rejection by CD4? effector memory T cells. Eur J Immunol 41:2782-92|
|Bandyopadhyay, Arunima; Fine, Rebecca L; Demento, Stacey et al. (2011) The impact of nanoparticle ligand density on dendritic-cell targeted vaccines. Biomaterials 32:3094-105|
Showing the most recent 10 out of 21 publications